719310-31-3

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 6-bromO-2,3-dihydrobenzo[b][1,4]oxazine-4-carboxylate is used as a synthetic intermediate for the preparation of various organic compounds. Its presence of a bromine atom and carboxylate group allows for a range of chemical reactions, facilitating the synthesis of diverse molecular structures.
Used in Pharmaceutical Research:
In the pharmaceutical industry, tert-butyl 6-bromO-2,3-dihydrobenzo[b][1,4]oxazine-4-carboxylate is utilized as a key building block in the development of new drugs. Its unique structural elements, including the benzooxazine core and the functional groups, contribute to the design of novel pharmaceutical agents with potential therapeutic applications.
Used in Medicinal Chemistry:
Tert-butyl 6-bromO-2,3-dihydrobenzo[b][1,4]oxazine-4-carboxylate is employed as a molecular scaffold in medicinal chemistry. Its structural features enable the attachment of various functional groups, which can be tailored to target specific biological receptors or enzymes, thereby enhancing the compound's pharmacological properties and potential therapeutic effects.
Used in Drug Development:
In the field of drug development, tert-butyl 6-bromO-2,3-dihydrobenzo[b][1,4]oxazine-4-carboxylate is used as a precursor in the synthesis of new pharmaceuticals. Its versatility and reactivity make it an attractive candidate for the creation of compounds with improved efficacy, selectivity, and safety profiles.
Overall, tert-butyl 6-bromO-2,3-dihydrobenzo[b][1,4]oxazine-4-carboxylate is a valuable chemical entity with broad applications across various scientific disciplines, particularly in the realms of organic synthesis, pharmaceutical research, and drug development. Its unique structural attributes and potential for further functionalization make it a promising candidate for the advancement of novel therapeutic agents and the improvement of existing pharmaceuticals.

Upstream product

• 719310-30-2 tert-butyl (5-bromo-2-hydroxyphenyl)carbamate 
• 106-93-4 ethylene dibromide 
• 1235451-65-6 5-bromo-2-(2-bromoethoxy)benzenamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 105655-01-4 6-bromo-3, 4-dihydro-2H-benzo[β][1, 4]oxazine 
• 40925-68-6 2-amino-4-bromo-phenol 
• 7693-52-9 4-bromo-2-nitrophenol 

Relevant academic research and scientific papers

OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING INHIBITORS

The instant invention provides compounds of formula I which are STING inhibitors, and as such are useful for the treatment of STING-mediated diseases such as inflammation, asthma, COPD and cancer.

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of 5,5-dimethyl-5,6-dihydro-1,3-benzothiazol-7(4H)-one and 7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted benzofused mor

BENZOXAZINES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3KS

The present invention provides compounds of Formula (I) wherein W, Q, E, D, A, L, R6, R7, R8, Y, K, R9, R10,G, the dashed bond between D and E, and the double bond denoted "*" have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I).